Atea Pharmaceuticals
Corporate brand
UnclaimedAtea Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on discovering and developing oral antiviral therapeutics for serious viral diseases.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases. The company is currently focused on developing orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) and hepatitis E virus (HEV). Its lead regimen, bemnifosbuvir/ruzavir, is advancing in a global Phase 3 development program for HCV, and in July 2026, the company announced that its Phase 3 trial C-BEYOND achieved its primary and secondary endpoints.
History
Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases. The company is focused on developing orally-available direct-acting antiviral agents for the treatment of hepatitis C virus (HCV) and hepatitis E virus (HEV). Its lead regimen, bemnifosbuvir/ruzavir, is advancing in a global Phase 3 development program for HCV. In July 2026, Atea announced that its Phase 3 trial C-BEYOND achieved its primary and secondary endpoints.
Recent events
Roche and Atea announce AT-527 collaboration[6]
Roche and Atea Pharmaceuticals announced a collaboration to develop, manufacture, and distribute AT-527, an investigational oral antiviral being studied for COVID-19. Roche is responsible for distribution outside the United States; Atea is responsible for U.S. distribution, with an option to request Genentech’s support.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/atea-pharmaceuticals-united-states · Editorial policy · How profiles are compiled